Actinogen Medical (ASX:ACW) dosed the first participant of a phase 2b/3 trial in the US of XanaMIA in patients with biomarker-positive mild to moderate Alzheimer's disease, according to a Monday filing with the Australian bourse.
The study aims to enroll 220 participants with elevated levels of the Alzheimer's disease biomarker pTau181, the filing said. The improvement in the Clinical Dementia Rating-Sum of Boxes scale is the primary endpoint, and the Amsterdam Activity of Daily Living scale is the secondary endpoint.
Participants will receive either 10 mg of the drug candidate or placebo daily for 36 weeks, per the filing.
Company shares rose nearly 7% in recent Monday trade.
Price (AUD): $0.03, Change: $+0.002, Percent Change: +6.45%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。